

6. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. *N Engl J Med*. 2020;383(19):1813-1826.
7. Kalil AC, Patterson TF, Mehta AK, et al; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. *N Engl J Med*. 2021;384(9):795-807.
8. An EUA for bamlanivimab-A monoclonal antibody for COVID-19. *JAMA*. 2021;325(9):880-881.
9. Weinreich DM, Sivapalasingam S, Norton T, et al; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N Engl J Med*. 2021;384(3):238-251.
10. Recovery_Collaborative_Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384(8):693-704.
11. Villar J, Ferrando C, Martínez D, et al; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med*. 2020;8(3):267-276.
12. Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. *Leukemia*. 2020;34(11):3047-3049.
13. Sinisalo M, Aittoniemi J, Käyhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2003;44(4):649-652.
14. Pleyer C, Ali MA, Cohen JL, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. *Blood*. 2021;137(2):185-189.
15. Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). *Leukemia*. 2021;35(3):737-746.
16. Sinisalo M, Aittoniemi J, Oivanen P, Käyhty H, Olander RM, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. *Br J Haematol*. 2001;114(1):107-110.
17. Zent CS, Brady MT, Delage C, et al. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. *Leukemia*. 2021;35(6):1788-1791.
18. Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. *Vaccine*. 2001;19(13-14):1671-1677.
19. Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients—preliminary report. *PLoS One*. 2014;9(12):e114966.
20. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). *BMJ*. 1998;317(7172):1572-1580.
21. Stata Statistical Software: Release 16 [computer program]. College Station, TX: StataCorp LLC; 2019.
22. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. *J Am Geriatr Soc*. 2008;56(10):1926-1931.
23. Recovery_Collaborative_Group, Horby P, Mafham M, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med*. 2020;383(21):2030-2040.
24. Simonovich VA, Burgos Pratz LD, Scibona P, et al; PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. *N Engl J Med*. 2021;384(7):619-629.

DOI 10.1182/blood.2021011841

© 2021 by The American Society of Hematology

TO THE EDITOR:

Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion

Annalisa Astolfi,^{1,*} Riccardo Masetti,^{2,*} Valentina Indio,³ Salvatore Nicola Bertuccio,⁴ Daria Messelodi,⁴ Simone Rampelli,⁵ Davide Leardini,⁶ Matteo Carella,⁷ Salvatore Serravalle,² Virginia Libri,² Jessica Bandini,² Stefano Volinia,¹ Marco Candela,⁵ and Andrea Pession²

¹Department of Translational Medicine, University of Ferrara, Ferrara, Italy; ²Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ³Interdepartmental Center Alma Mater Institute on Healthy Planet, ⁴Department of Medical and Surgical Sciences, ⁵Unit of Holobiont Microbiome and Microbiome Engineering, Department of Pharmacy and Biotechnology, ⁶Residency School of Pediatrics, and ⁷Residency School of Hematology, University of Bologna, Bologna, Italy

The treatment of patients with acute promyelocytic leukemia (APL) can serve as a paradigm for cancer therapy.¹ The outcome of this disease, in adults and in children, has significantly improved with the introduction of target-specific agents, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), providing long-term survival for most patients.^{2,3} Although morphologic and clinical suspicion is sufficient to immediately initiate ATRA, definitive diagnosis relies on the demonstration of PML/RARA translocation, on alternative RARA rearrangements represented by RARA gene fusion to other partners, cryptic insertion into the PML gene, or vice versa that altogether occur in more than 98% of APL cases.⁴⁻⁶ Here we describe an even more challenging situation where all conventional diagnostic approaches failed to detect an oncogenic event associated with the diagnosis of APL.

A 6-year-old girl was admitted to the emergency department with a 3-day history of shoulder pain and fever. On physical examination, she presented with pallor and ecchymosis of the lower limbs. A full blood count showed a hemoglobin concentration of 9.7 g/dL, and leukocyte and platelet counts of $2.8 \times 10^3/\mu\text{L}$ and $101 \times 10^3/\mu\text{L}$, respectively. Coagulation tests showed consumptive coagulopathy with slightly prolonged prothrombin and activated partial thromboplastin times, an increased D-dimer concentration, and hypofibrinogenemia. A peripheral blood smear showed atypical promyelocytes packed with numerous azurophilic granules (Figure 1A), whereas analysis of the bone marrow aspirate demonstrated markedly hypercellular marrow containing 85% abnormal promyelocytes with Auer rods (CD33⁺, CD13⁺, CD38⁺, CD99⁺, HLA-DR^{low}), with strong and diffuse reactivity to




Figure 1. Morphologic features of the APL case and characterization of the TTMV/RARA chimeric fusion transcript. (A) Morphology of the case of APL, negative for *RARA* rearrangement. Nuclear size and shape are irregular, whereas the cytoplasm is for the most part occupied by densely packed granules. (B) Average relative expression level from WTS data of *RARA* exons 2 and 3, and the expressed intronic region is shown for the index case (blue squares) and for another 12 AMLs with known chromosomal aberrations. (C) Schematic representation of the fusion between the TTMV sequence and *RARA* exon 3. The chimeric transcript shows the conserved TTMV UTR sequence followed by the ORF2, immediately upstream of the short sequence of retained *RARA* intron 2, in frame with the full *RARA* exon 3. A new splicing event that joins this part of the retained intron 2 to exon 3 and removes the intervening intronic sequence occurs during splicing. Some representative sequencing reads that support the presence of the fusion transcript are shown. The exon–intron gene structure and the location of the integrated viral sequence is indicated at the bottom. (D–E) Sanger sequencing electropherograms of the downstream (D) and upstream (E) breakpoints of TTMV integration on the leukemia relapse sample genomic DNA. (F) Detection of viral integration with primers common to the 3 Anelloviruses TTV, TTMDV, and TTMV (NG779/NG782), and those specific only for TTMV (NG792/NG791), in genomic DNA of the relapsed APL case and in another 6 AML samples. (G–H) Detection of the TTMV/RARA chimeric fusion in genomic DNA (G) and cDNA (H) in sequential samples of the APL case from diagnosis to relapse, during remission–induction therapy, and after HSCT. (I) Quantitative real-time PCR detection of the TTMV/RARA fusion transcript decrease during induction therapy and after HSCT.

myeloperoxidase staining. Molecular analysis was negative for *PML/RARA* fusions, and karyotype analysis did not show t(15;17)(q24;q21). Fluorescence in situ hybridization with *RARA* break-apart probe confirmed the negativity of all *RARA* rearrangements and of the cryptic *RARA* gene insertion. Based on the characteristic morphologic features, the review of the peripheral blood and bone marrow was consistent with a diagnosis of hypergranular (or typical) APL, and therapy with ATRA was immediately started. The patient received treatment combining standard induction acute myeloid leukemia therapy and ATRA, followed by 3 high-dose cytarabine-based courses of consolidation therapy. Complete remission was achieved after the first induction cycle and persisted until the end of treatment.

Eight months later, the child presented with fever, hemorrhagic findings, and abdominal and muscular pain. Bone marrow aspiration revealed an APL relapse with the same morphologic and immunophenotypic characteristics of the diagnosis, as well as a normal karyotype and the absence of the *PML/RARA* rearrangement and its isoforms.

Whole-transcriptome sequencing (WTS) of the relapse sample was then carried out, showing the aberrant expression of a small portion of *RARA* intron 2 (Figure 1B), not belonging to any known isoform and not expressed in a series of other pediatric acute myeloid leukemias (AMLs). The 5' sequence extension from *RARA* exon 3 revealed the abundant presence of a fusion




Figure 2. Phenotypic characterization of TTMV/RARA fusion transcript. (A) Detection of the TTMV/RARA chimeric fusion in cDNA of patient 2 diagnosis and relapse and of the index case for comparison. Patient 2 carried a longer insert sequence from TTMV ORF2, with respect to the index case (Pt1). (B) Overexpression of the top-scoring M3-AML-specific genes in the 2 cases carrying TTMV-RARA chimeric fusion (blue bars) similarly to the 11 APL cases from the SRA bioproject PRJNA721935 (red bars) and with respect to another 15 non-APL AML samples lacking cytogenetic and molecular aberrations (light green bars). The plot reports gene expression quantification as $\log_2$ ratios of transcripts per kilobase million (TPM); P value vs non-APL AML: $P < .05$; $**P < .01$; $***P < .001$. (C) Expression of TTMV-RARA by quantitative PCR in the HEK-293 cell line either parental or transfected with cloned full-length TTMV-RARA fusion transcript: $P < .0001$. (D) Flow cytometry assessment of TTMV/RARA fusion protein expression evaluated by means of AcGFP positivity in HEK-293 cells transfected with cloned full-length TTMV-RARA in frame with the AcGFP fluorescent tag sequence. (E) Effect of different ATRA concentrations on cell growth of U937 cells transfected with cloned full-length TTMV-RARA compared with the parental cell line after 4 days of treatment ($*P < .05$; $**P < .01$; $***P < .001$).

transcript involving the integration of 209 nucleotides upstream of exon 3, linked by the previously identified short sequence of retained intron 2. The insertion was located at chr17:40334196 and estimated to be 1045 bp in size, of which only the last 209 nucleotides were expressed in the fusion transcript, in-frame with RARA exon 3, and linked by 38 nucleotides of retained intron.

The integrated sequence was not homologous to any human sequence but revealed a significant alignment to different Anelloviridae isolates from torque teno Mini virus (TTMV; 67% to 69% coverage; 74% to 85% identity; Figure 1C-E). It also showed the putative conserved domain of the Torque Teno Open Reading Frame 2 (ORF2) superfamily in the coding region (E value = $3.44e-09$), with a protein identity of 48% and a coverage of 72% with respect to TTMV-ORF2. This ORF displays the conserved amino acid motif $WX_7HX_3CXCX_5H$ located at the N terminus, shared among all anelloviruses. The presence of the sequence mapping to the highly conserved Anellovirus untranslated region (UTR) was identified,^{7,8} specifically the 1 characterizing TTMV isolates,⁷ only in the index case and not in other 6 AML DNAs (Figure 1F). The full-length TTMV/RARA fusion transcript was predicted to encode a 485-amino-acid protein containing the DNA-binding and ligand-binding

domain of RARA. No evidence of the TTMV/RARA fusion sequence was found in AML samples from Leucegene and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) cohorts and in a publicly available dataset of APL, that anyway did not include any case negative for known RARA rearrangement.

The patient received a combination of ATRA and ATO according to emerging evidence⁹⁻¹⁴ and to the discovery of the novel RARA fusion transcript. Therapy consisting of 2 courses of ATO and ATRA was administered. Complete morphologic remission was achieved on day +21 of the first cycle. After 2 consolidation courses of ATO, given the availability of an HLA-matched sibling donor, she underwent hematopoietic stem cell transplantation (HSCT), resulting in a second complete remission. Bone marrow evaluations performed after HSCT confirmed complete morphologic remission, and analysis of the peripheral blood cells showed stable full donor chimerism. The patient is presently alive and well at 4 years after HSCT. Molecular analysis of leukemic samples before HSCT confirmed the presence of TTMV DNA integration in genomic DNA upstream of RARA exon 3 by polymerase chain reaction (PCR), whereas reverse transcription (RT)-PCR showed the expression of the chimeric fusion in both the diagnosis and the relapse samples (Figure 1G-H). Quantitative RT-PCR revealed the

progressive decrease of RARA fusion transcript expression along with remission-induction therapy, with complete clearance of the pathogenic allele after HSCT (Figure 1I).

A retrospective *in silico* analysis in our WTS database of 22 pediatric cytogenetically normal AML cases identified a second case of TTMV integration upstream of RARA exon 3 in a 3-year-old child affected by an AML lacking any cytogenetic abnormality or pathogenic somatic mutation. The integrated TTMV sequence was highly homologous to that of the index case (97.1% homology in the overlapping sequence), even if the expressed sequence was longer (328 bp; Figure 2A). The insertion was located upstream of a different segment of retained intron at chr17:40333779, in which only the last 328 nucleotides were expressed in the fusion transcript, in-frame with RARA exon 3, and linked by 45 nucleotides of retained intron. Actually, the RARA intron 2 is 16.9 kb in length, and, in all PML/RARA-rearranged APL, the breakpoints are dispersed throughout the RARA intron 2 both within repetitive and unique regions.¹⁵ To the best of our knowledge, neither patient had clinical evidence of immune deficiency.

To ascertain that both patients harbored transcriptionally active RARA rearrangements, we analyzed the expression of the M3-oncogenic signature,¹⁶ showing that only the 2 cases displayed the overexpression of the top-scoring M3-specific genes, similarly to other pediatric APL and with respect to non-APL AML represented by normal-karyotype AMLs (Figure 2B). Last, to prove that the viral chimeric fusion was transcriptionally functional, we expressed the entire coding sequence of TTMV/RARA in frame with Aequorea coerulescens (AcGFP) fluorescent tag into HEK-293 cells, which resulted in a high expression of the chimeric transcript (Figure 2C) and in the presence of a significant population of AcGFP-positive cells (Figure 2D). Moreover, we showed that, besides increasing the percentage of CD11b⁺ cells, treatment with ATRA induced a significant decrease in cell growth of the U937 myeloid leukemia cell line transduced with TTMV/RARA compared with the parental cell line (Figure 2E), proving that TTMV viral insertion upstream of RARA exon 3 produces a functional chimeric protein.

Virus infections cause at least 12% of human cancers, but this is the first report suggesting a direct oncogenic role for an isolate of the Anelloviridae family. Anelloviruses are nonenveloped, circular, single-stranded DNA viruses,¹⁷ recently identified as one of the prevalent components of the human blood virome.¹⁸ Because Anelloviruses appear to be ubiquitous in the human population, are acquired very early in life, and maintain persistent active infections, they are thought of as nonpathogenic to human beings. However, increased viremia levels of Anelloviruses have been found in immune-suppressed individuals,¹⁹ whereas Anelloviridae viral load was linked to long-term nonprogression in HIV-infected children,²⁰ and TTMV was associated with overall survival in pediatric patients undergoing lung transplant,²¹ suggesting that these viruses are normally kept under immunologic control. Nevertheless, this is the first report supporting a direct role of TTMV in malignant transformation, partly reinforced by the report of novel TTMV isolates in the plasma of patients with lymphoma or multiple myeloma.^{22,23}

In summary, we herein report the first case of childhood APL carrying a TTMV/RARA chimeric transcript successfully treated with

ATRA and ATO and subsequent HSCT, which supports the need to investigate the putative oncogenic role of TTMV in hematologic malignancies.

Acknowledgments

This work was partially supported by Associazione Italiana per la Ricerca sul Cancro grant MFAG2016, Id.19117 (R.M.) and University of Ferrara grant FIR-2020 (A.A.).

Authorship

Contribution: A.A., D.M., S.N.B., and V.L. performed NGS and molecular analyses; A.A. and R.M. designed the project and supervised the team-work; V.L., S.V., S.R., and M. Candela performed bioinformatic analyses; R.M., D.L., M. Carella, and A.P. collected clinical data; S.S. performed cytogenetic analyses; J.B. performed flow cytometry; A.P. supervised the study; and A.A., R.M., V.L., and A.P. analyzed data and wrote the paper, with contributions from all coauthors.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: A.A., 0000-0002-2732-0747; R.M., 0000-0002-1264-057X; V.L., 0000-0002-8854-3821; S.N.B., 0000-0002-5428-6716; D.M., 0000-0003-2242-3998; S.R., 0000-0002-5655-6695; D.L., 0000-0002-4673-5876; M. Carella, 0000-0001-5997-6452; S.S., 0000-0003-1304-614X; V.L., 0000-0001-5064-5382; S.V., 0000-0003-0910-3893; M. Carella, 0000-0001-7420-790X; A.P., 0000-0002-0379-9562.

Correspondence: Andrea Pession, Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, via Massarenti 11, 40138 Bologna, Italy; e-mail: andrea.pession@unibo.it.

Footnotes

Submitted 25 March 2021; accepted 4 August 2021; prepublished online on *Blood* First Edition 25 August 2021. DOI 10.1182/blood.2021011677.

*A.A. and R.M. contributed equally to this study.

Whole transcriptome sequencing data are available at the GEO repository with accession no. GSE169521.

Original data are available by e-mail request to the corresponding author.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

REFERENCES

1. de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. *Cancer Cell*. 2017;32(5):552-560.
2. Testi AM, D'Angiò M, Locatelli F, Pession A, Lo Coco F. Acute promyelocytic leukemia (APL): comparison between children and adults. *Mediterr J Hematol Infect Dis*. 2014;6(1):e2014032.
3. Masetti R, Vendemini F, Zama D, Biagi C, Gasperini P, Pession A. All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. *Expert Rev Anticancer Ther*. 2012;12(9):1191-1204.
4. Abela O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. *Br J Haematol*. 2014;164(1):24-38.
5. Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. *Blood*. 2000;96(4):1297-1308.

6. Rashidi A, Fisher SI. FISH-negative, cytogenetically cryptic acute promyelocytic leukemia. *Blood Cancer J*. 2015;5(6):e320.
7. Ninomiya M, Takahashi M, Nishizawa T, Shimosegawa T, Okamoto H. Development of PCR assays with nested primers specific for differential detection of three human anelloviruses and early acquisition of dual or triple infection during infancy. *J Clin Microbiol*. 2008;46(2):507-514.
8. Okamoto H, Nishizawa T, Tawara A, et al. Species-specific TT viruses in humans and nonhuman primates and their phylogenetic relatedness. *Virology*. 2000;277(2):368-378.
9. Lo-Coco F, Avvisati G, Vignetti M, et al; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*. 2013;369(2):111-121.
10. Strocchio L, Gurnari C, Santoro N, et al. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. *Br J Haematol*. 2019;185(2):360-363.
11. Cheng Y, Zhang L, Wu J, Lu A, Wang B, Liu G. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. *Eur J Haematol*. 2013;91(6):483-489.
12. Creutzig U, Dworzak MN, Bochennek K, et al. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. *Pediatr Blood Cancer*. 2017;64(8):e26461.
13. Testi AM, Moleti ML, Canichella M, et al. Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. *Leuk Lymphoma*. 2017;58(4):999-1001.
14. Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. *Blood*. 2018;132(4):405-412.
15. Reiter A, Saussele S, Grimwade D, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. *Genes Chromosomes Cancer*. 2003;36(2):175-188.
16. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. *J Clin Invest*. 2009;119(6):1714-1726.
17. Biagini P. Classification of TTV and related viruses (anelloviruses). *Curr Top Microbiol Immunol*. 2009;331:21-33.
18. De Vlaminc I, Khush KK, Strehl C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. *Cell*. 2013;155(5):1178-1187.
19. Focosi D, Antonelli G, Pistello M, Maggi F. Torquetenovirus: the human virome from bench to bedside. *Clin Microbiol Infect*. 2016;22(7):589-593.
20. Mwesigwa S, Williams L, Retshabile G, et al; TrypanoGEN Research Group. Unmapped exome reads implicate a role for Anelloviridae in childhood HIV-1 long-term non-progression. *NPJ Genom Med*. 2021;6(1):24.
21. Blatter JA, Sweet SC, Conrad C, et al. Anellovirus loads are associated with outcomes in pediatric lung transplantation. *Pediatr Transplant*. 2018;22(1):e13069.
22. Pan S, Yu T, Wang Y, et al. Identification of a Torque Teno Mini virus (TTMV) in Hodgkin's lymphoma patients. *Front Microbiol*. 2018;9:1680.
23. Bal A, Oriol G, Josset L, et al. Metagenomic investigation of Torque Teno Mini virus-SH in hematological patients. *Front Microbiol*. 2019;10:1898.

DOI 10.1182/blood.2021011677

© 2021 by The American Society of Hematology

TO THE EDITOR:

COVID-19 as a potential trigger of complement-mediated atypical HUS

Carine El Sissy,^{1,2} Antonin Saldman,^{1,2} Gilbert Zanetta,³ Paula Vieira Martins,¹ Coralie Poulain,⁴ Raphaël Cauchois,⁵ Gilles Kaplanski,^{5,6} Jean-Pierre Venetz,⁷ Mickaël Bobot,⁸ Hélène Dobosiewicz,⁹ Laurent Daniel,¹⁰ Marie Koubi,⁶ Salima Sadallah,¹¹ Samuel Rotman,¹² Christiane Mousson,³ Manuel Pascual,⁷ Véronique Frémeaux-Bacchi,^{1,2,13} and Fadi Fakhouri¹⁴

¹Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie, Paris, France; ²Paris University, Paris, France; ³Department of Nephrology-Intensive Care, University Hospital, Dijon, France; ⁴Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France; ⁵Hôpitaux de Marseille, CHU de la Conception, Service de Médecine Interne et immunologie clinique, Marseille, France; ⁶Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille Université and C2VN, Inserm U1263, Inrae 1260, Marseille, France; ⁷Transplantation Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; ⁸Hôpitaux de Marseille, Centre de Néphrologie et Transplantation Rénale, CHU de la Conception, Marseille, France; ⁹Service de Néphrologie, Dialyse et Transplantation, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France; ¹⁰Service d'Anatomie Pathologique, Hôpital de La Timone, AP-HM, Aix-Marseille Université, Marseille, France; ¹¹Service of Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; ¹²Service of Clinical Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; ¹³Inflammation, Complement and Cancer Team, Cordeliers Research Center, INSERM Unité Mixte de Recherche (UMR) S1138, Paris, France; and ¹⁴Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Endothelial cell (EC) injury has emerged as a hallmark of infection resulting from severe respiratory coronavirus 2.¹⁻³ Complement activation or dysregulation is another notable feature of COVID-19,^{4,5} and elevated plasma levels of sC5b-9, a marker of activation of the complement terminal pathway, have been reported in up to 2/3 of COVID-19 patients,⁶ and correlate with disease severity.^{4,6}

Complement dysregulation is also a well-established pathogenic mechanism of a rare form of renal thrombotic microangiopathy

(TMA), the atypical hemolytic uremic syndrome (aHUS), triggered by complement-induced EC damage.⁷

To date, renal TMA has been very rarely documented in the COVID-19 setting.^{8,9} We report on 5 patients with COVID-19-associated renal TMA, among whom 4 tested patients carried complement genetic susceptibility factors for aHUS.

Patients with COVID-19-associated renal TMA were identified using the databases of the French HUS Registry and the